Employment |
No Relationships to Disclose |
|
|
Leadership |
Company: Capio BioSciences |
Recipient: An Immediate Family Member |
Company: Archimmune Therapeutics |
Recipient: An Immediate Family Member |
|
Stock and Other Ownership Interests |
Company: Capio Biosciences |
Recipient: An Immediate Family Member |
Company: Archimmune Therapeutics |
Recipient: An Immediate Family Member |
Company: Nanorobotics |
Recipient: An Immediate Family Member |
|
Honoraria |
Company: Exelixis |
Recipient: You |
Company: Genentech/Roche |
Recipient: You |
Company: MJH Life Sciences |
Recipient: You |
Company: Pacific Genuity |
Recipient: You |
|
Consulting or Advisory Role |
Company: Janssen |
Recipient: You |
Company: Genentech/Roche |
Recipient: You |
Company: Sanofi |
Recipient: You |
Company: Exelixis |
Recipient: You |
Company: AstraZeneca |
Recipient: You |
Company: Pfizer |
Recipient: You |
Company: Bristol-Myers Squibb |
Recipient: You |
Company: Foundation Medicine |
Recipient: You |
Company: Pharmacyclics |
Recipient: You |
Company: Amgen |
Recipient: You |
Company: Merck |
Recipient: You |
Company: Seattle Genetics |
Recipient: You |
Company: Dendreon |
Recipient: You |
Company: Calithera Biosciences |
Recipient: You |
|
Speakers' Bureau |
Company: Exelixis |
Recipient: You |
Company: Genentech/Roche |
Recipient: You |
Company: Genomic Health |
Recipient: You |
Company: Sanofi/Aventis |
Recipient: You |
|
Research Funding |
Company: Astellas Pharma |
Recipient: You |
Company: Janssen |
Recipient: Your Institution |
Company: Acerta Pharma |
Recipient: Your Institution |
Company: Pfizer |
Recipient: Your Institution |
Company: Merrimack |
Recipient: Your Institution |
Company: Stem CentRx |
Recipient: Your Institution |
Company: Novartis |
Recipient: Your Institution |
Company: OmniSeq |
Recipient: Your Institution |
Company: Personal Genome Diagnostics |
Recipient: Your Institution |
Company: Regeneron |
Recipient: Your Institution |
Company: Merck |
Recipient: Your Institution |
Company: Mirati Therapeutics |
Recipient: Your Institution |
|
Patents, Royalties, Other Intellectual Property |
Please describe: Circulating tumor cell novel capture by c-MET technology |
Recipient: Your Institution |
Please describe: Prochelators as Targeted Prodrugs for Prostate Cancer |
Recipient: Your Institution |
|
Expert Testimony |
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses |
Company: Acerta Pharma |
Recipient: You |
Company: Genomic Health |
Recipient: You |
Company: AstraZeneca |
Recipient: You |
|
Other Relationship |
No Relationships to Disclose |
|
|
(OPTIONAL) Uncompensated Relationships |
No Relationships to Disclose |
|
|
(OPTIONAL) Open Payments Link |
No Relationships to Disclose |
|
|